The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer.
 
Shumei Kato
No Relationships to Disclose
 
Filip Janku
No Relationships to Disclose
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Aung Naing
No Relationships to Disclose
 
Daniel D. Karp
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); Celgene (Inst); EMD Serono (Inst); Foundation Medicine (Inst); NCCN (Inst)
 
Vivek Subbiah
No Relationships to Disclose
 
Ralph Zinner
No Relationships to Disclose
 
Wen-Jen Hwu
No Relationships to Disclose
 
Milind M. Javle
No Relationships to Disclose
 
Kristin L. Parkhurst
No Relationships to Disclose
 
Nishma M. Ramzanali
No Relationships to Disclose
 
Razelle Kurzrock
Stock and Other Ownership Interests - RScueRx
Honoraria - AACR; ASCO; Cancer Treament Centers of America; Cedars-Sinai; Clearview Healthcare Partners; CTRC-EAB San Antonio; Frankel Group; Janssen; Jubilant Biosys; Lynx Group; Merck; NCCN; SAIC NCI CCCT Investigational Drug Steering Committee; Segal Cancer Center; The Dedham Group; University of Arizona; Usha Mahajani Foundation
Consulting or Advisory Role - AACR; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; GlaxoSmithKline; GlaxoSmithKline; Merck; Merck; Novartis; Roche/Genentech; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - Cancer Treament Centers of America; EMD Serono; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Global Biomarkers Consortium; ICRP; WIN Pharma; WIN Pharma
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche; Sysmex
Consulting or Advisory Role - Genentech; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical
 
Young Kwang Chae
Research Funding - MedImmune (Inst)
 
Kevin Kim
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - ARMO BioSciences; AstraZeneca; Celgene; EMD Serono; Genmab; GlaxoSmithKline; Incyte; Kolltan Pharmaceuticals; MedImmune; Millennium; Novartis; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - EMD Serono; Millennium; Sarah Cannon Research Institute